U.S. Stem Cell, Inc. (USRM)
| Market Cap | 662.00 |
| Revenue (ttm) | 82.05K |
| Net Income (ttm) | -2.86M |
| Shares Out | 661.51M |
| EPS (ttm) | -0.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 56,557 |
| Average Volume | 567,647 |
| Open | 0.0000 |
| Previous Close | n/a |
| Day's Range | 0.0000 - 0.0000 |
| 52-Week Range | 0.0000 - 0.0002 |
| Beta | -114.05 |
| RSI | 40.09 |
| Earnings Date | Apr 14, 2026 |
About U.S. Stem Cell
U.S. Stem Cell, Inc., a biotechnology company, engages in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company’s lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells or cells from a patient’s body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-der... [Read more]
Financial Performance
In 2022, U.S. Stem Cell's revenue was $82,049, a decrease of -59.13% compared to the previous year's $200,749. Losses were -$2.86 million, -13.06% less than in 2021.
Financial StatementsNews
Mark Borman Appointed Chairman of the Board of USRM
SUNRISE, FL / ACCESSWIRE / March 9, 2022 / U.S. Stem Cell, Inc. (OTC PINK:USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutio...